D. Boral Capital Reiterates "Buy" Rating for Omeros (NASDAQ:OMER)

Key Points

• D. Boral Capital has reaffirmed a "buy" rating for Omeros (NASDAQ:OMER) with a target price of $36.00, indicating a potential upside of 249.31% from the current share price.
• Omeros reported a quarterly EPS of ($0.53), which exceeded analysts' expectations of ($0.55), alongside revenue of $28.60 million for the quarter.
• Institutional investors own 48.79% of Omeros stock, with significant recent increases in stakes from firms like Vanguard Group and Marshall Wace LLP.

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at D. Boral Capital in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $36.00 target price on the biopharmaceutical company's stock. D. Boral Capital's price target suggests a potential upside of 249.31% from the stock's current price.

A number of other brokerages have also commented on OMER. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research note on Friday, August 15th. Wall Street Zen upgraded shares of Omeros from a "sell" rating to a "hold" rating in a report on Saturday, September 20th. Weiss Ratings restated a "sell (d-)" rating on shares of Omeros in a report on Wednesday, October 8th. Finally, HC Wainwright reissued a "buy" rating and set a $9.00 price target on shares of Omeros in a research report on Friday, June 27th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $18.00.

Omeros Stock Performance

Omeros stock traded up $6.21 during midday trading on Wednesday, reaching $10.31. 41,223,968 shares of the stock were exchanged, compared to its average volume of 1,072,339. The company's fifty day moving average is $4.24 and its 200-day moving average is $4.50. The firm has a market cap of $701.43 million, a PE ratio of -4.87 and a beta of 2.32. Omeros has a 52 week low of $2.95 and a 52 week high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.02. The company had revenue of $28.60 million during the quarter, compared to the consensus estimate of $0.31 million. On average, sell-side analysts anticipate that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omeros

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Omeros by 3.0% in the 1st quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company's stock worth $26,610,000 after purchasing an additional 95,599 shares in the last quarter. Marshall Wace LLP increased its holdings in Omeros by 15.1% during the 2nd quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company's stock valued at $2,224,000 after purchasing an additional 97,224 shares in the last quarter. Bank of Montreal Can boosted its position in shares of Omeros by 1.4% in the 2nd quarter. Bank of Montreal Can now owns 571,095 shares of the biopharmaceutical company's stock worth $1,713,000 after purchasing an additional 8,000 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Omeros by 2.2% during the first quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company's stock worth $1,242,000 after acquiring an additional 3,321 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in shares of Omeros in the 1st quarter valued at about $1,118,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.